Intas Pharmaceuticals Limited — Rituximab Exporter Profile
Indian Pharmaceutical Exporter · #7 for Rituximab · $158.4K export value · DGFT Verified
Intas Pharmaceuticals Limited is the #7 Indian exporter of Rituximab with $158.4K in export value and 13 verified shipments. Intas Pharmaceuticals Limited holds a 0.8% market share in Rituximab exports across 4 countries. The company exports 75 pharmaceutical products worth $372.3M across 19 therapeutic categories.
Intas Pharmaceuticals Limited — Rituximab Export Profile: Buyers & Destinations
Where Does Intas Pharmaceuticals Limited Export Rituximab?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED ARAB EMIRATES | $69.3K | 4 | 44.8% |
| PAKISTAN | $36.7K | 5 | 23.8% |
| SURINAM | $30.5K | 3 | 19.7% |
| SURINAME | $18.0K | 1 | 11.7% |
Intas Pharmaceuticals Limited exports Rituximab to 4 countries. The largest destination is UNITED ARAB EMIRATES accounting for 44.8% of Intas Pharmaceuticals Limited's Rituximab shipments, followed by PAKISTAN (23.8%) and SURINAM (19.7%). These destinations reflect Intas Pharmaceuticals Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Rituximab from Intas Pharmaceuticals Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| ART INTERNATIONAL LTD | UNITED ARAB EMIRATES | $69.3K | 4 |
| SOMA PHARMA | SURINAM | $30.5K | 3 |
| HELIX PHARMA (PRIVATE) LIMITED | PAKISTAN | $22.5K | 3 |
| TO THE ORDER., | SURINAME | $18.0K | 1 |
| TO THE ORDER | PAKISTAN | $14.3K | 2 |
Intas Pharmaceuticals Limited supplies Rituximab to 5 buyers globally. The largest buyer is ART INTERNATIONAL LTD (UNITED ARAB EMIRATES), followed by SOMA PHARMA (SURINAM) and HELIX PHARMA (PRIVATE) LIMITED (PAKISTAN). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Rituximab Export Value and How Much Does Intas Pharmaceuticals Limited Contribute?
India exported $9.4M worth of Rituximab through 1,215 shipments from 164 suppliers to 104 countries, serving 292 buyers globally. Intas Pharmaceuticals Limited contributes $158.4K to this total, accounting for 0.8% of India's Rituximab exports. Intas Pharmaceuticals Limited ships Rituximab to 4 countries through 5 buyers.
What Is the Average Shipment Value for Intas Pharmaceuticals Limited's Rituximab Exports?
Intas Pharmaceuticals Limited's average Rituximab shipment value is $12.2K per consignment, based on 13 shipments totaling $158.4K. The largest destination is UNITED ARAB EMIRATES (44.8% of Intas Pharmaceuticals Limited's Rituximab exports).
How Does Intas Pharmaceuticals Limited Compare to Other Indian Rituximab Exporters?
Intas Pharmaceuticals Limited ranks #7 among 164 Indian Rituximab exporters with a 0.8% market share. The top 3 exporters are RELIANCE LIFE SCIENCES PRIVATE LIMITED ($4.1M), DR.REDDY'S LABORATORIES LTD ($3.2M), DR REDDYS LABORATORIES LIMITED ($550.0K). Intas Pharmaceuticals Limited processed 13 shipments to 4 destination countries.
What Rituximab Formulations Does Intas Pharmaceuticals Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| PHARMACEUTICAL DRUGS AND MEDICINE RITUXIMAB 500MG/50ML 1V XIMAB 500MG/50ML VIAL(PK)1X1 | $50.0K | 1 |
| PHARMA DRUGS AND MEDI RITUXIMAB 100MG/10ML 1V AS PER INV | $28.7K | 2 |
| PH.DRU.& MED.: MABTAS 500MG/50ML VIAL (RITUXIMAB CONCENTRATED SOLUTION FOR INFUSION 500MG/50ML) [100 PACK X 1X1] | $18.0K | 1 |
| PH.DRU.& MED.: MABTAS 500MG/50ML VIAL (RITUXIMAB CONCENTRATED SOLUTION FOR INFUSION 500MG/50ML) [1X1 VIAL] | $17.9K | 1 |
| PHARMACEUTICAL DRUGS AND MEDICINE - RITUXIMAB 100MG/10ML 1V - AS PER INVOICE | $14.3K | 2 |
| PH.DRU.& MED.: MABTAS 500MG/50ML VIAL (RITUXIMAB CONCENTRATED SOLUTION FOR INFUSION 500MG/50ML) [1X1 VIAL]VLS | $9.1K | 1 |
| PHARMA DRUGS AND MEDI RITUXIMAB 500MG/50ML 1V AS PER INV | $8.2K | 1 |
| FOC PHARMACEUTICAL DRUGS AND MEDICINE RITUXIMAB 500MG/50ML 1V FOC | $3.8K | 1 |
| PH.DRU.& MED.: MABTAS 100MG/10ML VIAL (RITUXIMAB CONCENTRATED SOLUTION FOR INFUSION 100MG/10ML) [1X1 VIAL] | $3.4K | 1 |
| PHARMA DRUGS AND MEDI RITUXIMAB 100MG/10ML 1V FOC SHPT AS PER INV | $1.1K | 2 |
Intas Pharmaceuticals Limited exports 10 distinct Rituximab formulations including tablets, capsules, syrups, and combination drugs. The top formulation is PHARMACEUTICAL DRUGS AND MEDICINE RITUXIMAB 500MG/50ML 1V X with 1 shipments worth $50.0K. Notable combination products include fixed-dose combinations with other active ingredients, meeting diverse global regulatory requirements.
How Does Intas Pharmaceuticals Limited Compare to Nearest Rituximab Exporters?
Exporters ranked immediately above and below #7 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 5 | HETERO BIOPHARMA LIMITED | $400.0K | 8 | 4 | $50.0K |
| 4 | MEDWISE OVERSEAS PRIVATE LIMITED | $250.0K | 5 | 1 | $50.0K |
| 7 | INTAS PHARMACEUTICALS LIMITED ★ | $158.4K | 13 | 4 | $12.2K |
| 6 | INVEX HEALTH PRIVATE LIMITED | $150.0K | 3 | 2 | $50.0K |
| 8 | J.A. UNITED EXPORTS PRIVATE LIMITED | $122.3K | 20 | 4 | $6.1K |
Intas Pharmaceuticals Limited ranks #7 among 164 Indian Rituximab exporters. Average shipment value of $12.2K compared to the market average of $57.4K. The closest competitors by value are HETERO BIOPHARMA LIMITED and MEDWISE OVERSEAS PRIVATE LIMITED.
Which Indian Ports Ship Rituximab Exports?
| Port | Shipments | % Share |
|---|---|---|
| SAHAR AIR | 389 | 32.0% |
| SAHAR AIR CARGO ACC (INBOM4) | 325 | 26.7% |
| Bombay Air | 85 | 7.0% |
| Bombay Air Cargo | 58 | 4.8% |
| HYDERABAD ACC (INHYD4) | 46 | 3.8% |
| DELHI AIR CARGO ACC (INDEL4) | 45 | 3.7% |
| DELHI AIR | 35 | 2.9% |
| AHEMDABAD AIR | 26 | 2.1% |
Geopolitical & Trade Policy Impact on Intas Pharmaceuticals Limited's Rituximab Exports
The current geopolitical landscape presents both challenges and opportunities for Indian pharmaceutical exporters like Intas Pharmaceuticals. The Israel-Iran tensions have led to increased security risks in the Strait of Hormuz and the Red Sea–Suez Canal corridor, prompting major carriers to reroute shipments around the Cape of Good Hope. This detour has extended transit times by 10–20 days and raised freight rates by 40–50% on key India–Europe routes, impacting the cost-effectiveness and timeliness of exports. (livemint.com)
Conversely, the ongoing US-China trade tensions have opened avenues for Indian pharmaceutical companies to capture a larger share of the U.S. market. Intas's acquisition of UDENYCA® and the FDA's acceptance of its biosimilar applications position the company to leverage these opportunities effectively. However, compliance with the European Union's Falsified Medicines Directive (FMD) remains a critical factor for market access. Intas's proactive approach in securing partnerships and ensuring regulatory compliance underscores its commitment to maintaining and expanding its presence in the European market.
Intas Pharmaceuticals Limited — Regulatory Compliance & Quality Standards
Maintaining stringent regulatory compliance is paramount for Indian pharmaceutical exporters. Intas Pharmaceuticals has demonstrated a strong commitment to adhering to international quality standards, as evidenced by its successful acquisitions and partnerships that necessitate compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP). The company's proactive engagement in regulatory processes, such as the FDA's acceptance of its Biologics License Application for DMB-3115, reflects its dedication to quality and compliance. (intaspharma.com) As global regulatory requirements continue to evolve, Intas's focus on quality assurance and compliance positions it favorably in the competitive pharmaceutical export market.
About Intas Pharmaceuticals Limited
Intas Pharmaceuticals Limited exports 75 products worth $372.3M. Beyond Rituximab, top products include Ras, Mycophenolate, Tacrolimus, Apixaban, Ezetimibe. View the complete Intas Pharmaceuticals Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Rituximab — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Rituximab shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Intas Pharmaceuticals Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 13 individual customs records matching Intas Pharmaceuticals Limited exporting Rituximab, covering 10 formulations to 4 countries via 5 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 104+ countries, 292+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Rituximab Export Data from Intas Pharmaceuticals Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Intas Pharmaceuticals Limited's Rituximab exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Intas Pharmaceuticals Limited
Full Company Profile →
75 products · $372.3M total trade · 19 categories
Rituximab Stats
Company Overview
Top Products by Intas Pharmaceuticals Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Intas Pharmaceuticals Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Rituximab. For current shipment-level data, contact TransData Nexus.